Literature DB >> 22469183

Long-term effect of chronic intravenous and inhaled nephrotoxic antibiotic treatment on the renal function of patients with cystic fibrosis.

Marius C Florescu1, Elizabeth Lyden, Peter J Murphy, Diana F Florescu, Jennifer Fillaus.   

Abstract

Cystic fibrosis (CF) patients have numerous infectious exacerbations requiring prolonged antibiotic treatments, some of which are nephrotoxic. Inhaled antibiotics can reach detectable serum levels. We studied the impact of chronic nephrotoxic antibiotic exposure on kidney function in CF population. We collected data retrospectively for 113 adult CF patients followed for 8.5 years. Fifty-seven (50.4%) were males and 56 (49.5%) females (mean age 31.7 years [SD 9.9]), of which 31% had diabetes and 9.7% had hypertension. Over 8.5 years follow up, there were no significant changes in blood urea nitrogen (BUN; P = 0.92) or creatinine (P = 0.2) in the whole group. 22% of patients had ≥1 episodes of acute kidney injury (AKI). The presence of AKI was associated with increased BUN (P = 0.002) and creatinine (P = 0.056) at the end of follow up. Use of intravenous colistin, gentamicin, tobramycin, or vancomycin did not correlate with increased BUN (P = 0.64; P = 0.49; P = 0.51; P = 0.47) or creatinine (P = 0.43; P = 0.49; P = 0.17; P = 0.2) after 8.5 years. Elevated tobramycin peak and trough levels did not correlate with increased BUN or creatinine. Inhaled colistin and gentamicin correlated with increased BUN (P = 0.009; P = 0.02) but not creatinine (P = 0.45; P = 0.46). Inhaled tobramycin did not correlate with increased BUN (P = 0.17) or creatinine (P = 0.58). Only inhaled colistin correlated with AKI episodes (P = 0.03). Chronic inhaled colistin and gentamicin are associated with an increase in BUN but not creatinine at the end of follow up. Inhaled colistin was associated with episodes of AKI. Well-managed intravenous use of nephrotoxic antibiotics in CF population is associated with no major long-term renal toxicity.
© 2012 The Authors. Hemodialysis International © 2012 International Society for Hemodialysis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22469183     DOI: 10.1111/j.1542-4758.2012.00675.x

Source DB:  PubMed          Journal:  Hemodial Int        ISSN: 1492-7535            Impact factor:   1.812


  6 in total

1.  Daily serum creatinine monitoring promotes earlier detection of acute kidney injury in children and adolescents with cystic fibrosis.

Authors:  Kevin J Downes; Marepalli B Rao; Laurie Kahill; Hovi Nguyen; John P Clancy; Stuart L Goldstein
Journal:  J Cyst Fibros       Date:  2014-04-06       Impact factor: 5.482

2.  Pharmacokinetics and pharmacodynamics of once-daily administration of intravenous tobramycin in adult patients with cystic fibrosis hospitalized for an acute pulmonary exacerbation.

Authors:  Jill M Butterfield; Thomas P Lodise; Scott Beegle; Jonathan Rosen; Joshua Farkas; Manjunath P Pai
Journal:  Antimicrob Agents Chemother       Date:  2013-07-29       Impact factor: 5.191

Review 3.  Colistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapy.

Authors:  Cordula Koerner-Rettberg; Manfred Ballmann
Journal:  Core Evid       Date:  2014-09-19

4.  Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients.

Authors:  Florian Stehling; Rainer Büscher; Jörg Grosse-Onnebrink; Peter F Hoyer; Uwe Mellies
Journal:  Pulm Med       Date:  2017-01-04

5.  Renal involvement and metabolic alterations in adults patients affected by cystic fibrosis.

Authors:  Silvia Lai; Sandro Mazzaferro; Anna Paola Mitterhofer; Enea Bonci; Paolo Giangreco Marotta; Francesco Pelligra; Manuel Murciano; Camilla Celani; Patrizia Troiani; Giuseppe Cimino; Paolo Palange
Journal:  J Transl Med       Date:  2019-11-25       Impact factor: 5.531

6.  Unknown Renal Impairment: A Rare Case of Inhaled Tobramycin Induced Acute Kidney Injury in a Cystic Fibrosis Patient.

Authors:  Tyler Miller; Cristina Pastuch; Lisa Garavaglia; Kelley Gannon; Anthony Parravani
Journal:  Antibiotics (Basel)       Date:  2021-04-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.